

Special Issue

Molecular Biomarkers in Colorectal Cancer

Message from the Guest Editor

Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality worldwide. In the past few decades, major advances in diagnostic endoscopic and imaging performance have resulted in earlier detection, while improvements in surgery, chemotherapy, and radiotherapy, and better pre- and postoperative care, have led to an improved survival of patients with CRC. Pathological TNM-stage at the time of diagnosis is still considered as the strongest predictor for CRC survival. However, there remains great inter-patient variability regarding survival. A combination of biochemical factors, histopathological features, genomic profile, microbiota, immune response to cancer, circulating cancer cells, and/or circulating tumor DNA are likely to influence prognosis independent of tumor stage. These markers may be used to (i) determine patient's prognosis, which could lead to more accurate diagnostic tests and efficient follow-up surveillance strategies; (ii) predict treatment outcome and guide the selection of the patients whose most likely take benefit from adjuvant treatment; and (iii) tailor systemic treatment and monitoring resistance in patients with metastatic disease.

Guest Editor

Prof. Dr. John Souglakos

Associate Professor of Medical Oncology, Laboratory of Translational Oncology, Faculty of Medicine, University of Crete, Department of Medical Oncology, University Hospital of Heraklion, Greece

Deadline for manuscript submissions

closed (31 July 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/64127

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)